Citadel Advisors
BBNX

Citadel Advisors’s Beta Bionics BBNX Stock Holding History

Citadel Advisors’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$633K Buy
40,400
+15,100
+60% +$180K ﹤0.01% 9317
2026
Q1 		$254K Buy
25,300
+15,000
+146% +$222K ﹤0.01% 10876
2025
Q4 		$314K Buy
+10,300
New +$275K ﹤0.01% 10029

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Citadel Advisors's BBNX Position: Q2 2026 in Review

Citadel Advisors sold out of Beta Bionics (BBNX) in Q2 2026, closing a stake of 52,142 shares — an estimated $620K sold.

Citadel Advisors first reported a position in BBNX in Q1 2025 and held it in 4 quarters. The position peaked at $11.6M in Q1 2025. 134 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Citadel Advisors reported no remaining Beta Bionics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 52,142 Beta Bionics shares in Q2 2026, an estimated $620K.
  • Citadel Advisors first reported a position in Beta Bionics in Q1 2025 and held it in 4 quarters.
  • Citadel Advisors's Beta Bionics position peaked at $11.6M in Q1 2025.
  • 134 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.